An over-the-counter supplement, a better score on a memory test: the connection is tempting. An Emory study does point to a signal involving vitamin D, but it does not show that taking more tablets protects against cognitive decline. The most useful point lies in the detail: the people concerned have a particular profile, and the amount studied exceeds the upper limit set in Europe for adults.
A signal involving twelve people
The US team studied 54 adults with mild cognitive impairment, diagnosed or suspected, and sleep problems. Their average age was 67. Vitamin D consumption was self-reported by questionnaire; the researchers did not randomly assign participants to take a supplement.
In the subgroup reporting at least 5,000 international units a day, which comprised twelve people, the MoCA cognitive test score was higher than among non-users. The adjusted difference was 3.78 points. The authors describe this as a preliminary finding, with statistical significance close to the chosen threshold. Lower doses were not associated with a significant result.
This snapshot taken at a single point in time therefore does not measure improvement after treatment. Nor does it track a reduction in dementia diagnoses. The scientific paper highlights two decisive limitations: no blood vitamin D measurements were available, and reverse causation remains possible. For example, people whose abilities are better preserved may find it easier to manage their supplements. Study published in Sleep Medicine.
Why “13% better” is not enough
In its communication of 19 August 2026, Emory describes the difference as a score more than 13% higher. The university notes that MoCA is used to assess cognitive abilities and that the study received funding from the National Institute on Aging. It also reports no significant difference between forms D2 and D3 in this sample. The university’s account.
For readers, three expressions must be kept separate: a higher score, improving memory and preventing a disease. The first describes a comparison. The second would require showing a change over time. The third would require follow-up and an outcome relating to the disease itself. Moving from one to another in a headline would make the figures tell a story they do not establish.
It would also be misleading to automatically calculate 13% of a test’s maximum score and announce a number of points gained. A proportion only makes sense in relation to its comparison base. Here, it is better to return to the published estimate rather than reconstruct an individual benefit.
Larger trials counsel caution
Two ancillary studies of the randomised VITAL trial examined supplementation of 2,000 international units a day. They included 3,424 participants assessed by telephone and 794 assessed in person, aged 60 or over. Over approximately two to three years, the researchers found no evidence of an overall slowing of cognitive decline compared with placebo. A favourable result in a subgroup of Black participants called for further research. VITAL results.
This work does not answer Emory’s question exactly: the dose, participants and protocol differ. Nevertheless, it prevents vitamin D from being presented as a proven memory protector for everyone. A targeted hypothesis may warrant a new trial without immediately becoming a general recommendation.
The right question for future research would be whether an intervention genuinely changes cognitive decline in the people concerned, how safe it is, and against which comparison group. Repeating a questionnaire with a larger population would improve precision; on its own, that would not replace a demonstration of efficacy.
The dose observed is not a dose to adopt
The European Food Safety Authority maintains the upper limit for vitamin D intake at 100 micrograms a day for adults. This safety limit is not an individual nutritional target. EFSA explains that specific needs, particularly in the presence of an illness, should be addressed with professional guidance. EFSA guidance.
The 5,000 international units mentioned in the study should therefore not be read as an instruction to buy supplements. The scientific paper itself notes the risk of hypercalcaemia associated with vitamin D toxicity. An exploratory finding does not justify taking several products or changing a prescription.
If you are experiencing memory or sleep difficulties, the priority is to find their cause with a professional, rather than choosing a high dose based on a percentage. To prepare for that discussion, bringing a list of supplements and their quantities makes it possible to talk about actual consumption. The value of this research is that it raises a specific question; its worth does not depend on promising an immediate solution.
